An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2008-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: multiplesingle anddosestolerabilityto determine
  Phrases that lowered it: volunteershealthymgopen labelsingle
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 236 (raises risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Primary purpose: basic science (lowers risk) · Design
• Sponsor's past trials: 411 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers NCT01588626 · started 2012 · scored riskier than 3% of active trials completed
• A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants NCT06502379 · started 2024 · scored riskier than 9% of active trials completed
• A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults NCT05437289 · started 2021 · scored riskier than 8% of active trials completed
• Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236 NCT00767052 · started 2008 · scored riskier than 7% of active trials completed
• Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017. NCT00799747 · started 2008 · scored riskier than 12% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.